Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Catheter Precision ( (VTAK) ).
Catheter Precision, Inc. held its 2025 annual meeting of stockholders on July 25, 2025, where the proposal for a reverse stock split was approved. The company’s board of directors decided on a 1-for-19 reverse stock split, which became effective on August 15, 2025. This move reduced the number of issued and outstanding shares significantly but did not alter the total authorized capital stock. The reverse split aimed to consolidate shares while maintaining stockholder equity and voting power, with adjustments made to stock options and warrants accordingly.
Spark’s Take on VTAK Stock
According to Spark, TipRanks’ AI Analyst, VTAK is a Neutral.
VTAK faces significant financial and operational challenges with ongoing losses and negative cash flow. Technical analysis indicates bearish momentum, and valuation is weak with a negative P/E. Corporate events offer both opportunities with product sales growth and risks from leadership changes and dilution concerns.
To see Spark’s full report on VTAK stock, click here.
More about Catheter Precision
Average Trading Volume: 14,738,400
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.59M
See more data about VTAK stock on TipRanks’ Stock Analysis page.